A New Weapon Against Superbugs: How a Novel Antibiotic Takes Aim

STATEN ISLAND, N.Y. – June 16, 2026

While the world has been rightly focused on viral pandemics, a quieter, more insidious crisis has been escalating in our hospitals and communities: the silent pandemic of antimicrobial resistance (AMR). Every year, bacteria evolve, rendering our most trusted antibiotics useless and turning common infections into life-threatening emergencies. The pipeline for new drugs has run dangerously dry, a market failure that costs millions of lives. But in a laboratory, a new image has come into focus, offering a glimmer of hope.

This week, Acurx Pharmaceuticals, a late-stage biopharmaceutical company, announced a significant scientific milestone in its quest to combat these “superbugs.” In a presentation at a scientific conference in the Netherlands, researchers from Leiden University Medical Center (LUMC) unveiled a near-atomic-level picture of how Acurx’s lead antibiotic candidate, ibezapolstat, works. The findings, a result of a public-private partnership backed by the Dutch government, don’t just validate a new drug; they illuminate a potential new strategy in our lopsided war against resistant bacteria.

A Precision Weapon in a Blunt-Force Fight

For decades, the primary approach of antibiotics has been akin to carpet-bombing. Broad-spectrum drugs kill the bad bacteria, but they also wipe out the beneficial bacteria that form our gut microbiome—a complex ecosystem vital for our health. This collateral damage can lead to devastating secondary infections, most notably from Clostridioides difficile (C. diff).

Acurx’s ibezapolstat is designed to be a sniper’s rifle. It’s the first in a new class of drugs that specifically inhibits an enzyme called DNA polymerase IIIC (PolC), which is essential for DNA replication in a wide range of Gram-positive bacteria but is absent in human cells and many of the gut’s helpful inhabitants. By blocking this enzyme, the drug stops dangerous bacteria like C. diff, MRSA, and VRE from multiplying, leading to their death while leaving the beneficial parts of the microbiome largely intact. This is what the company calls its Gram-Positive Selective Spectrum (GPSS®) approach.

Until now, the precise molecular basis for this selectivity was not fully understood. Using high-resolution cryo-electron microscopy—a technology that freezes molecules in motion to capture their structure—the LUMC research team, led by a group including Dr. Mia Urem, resolved the image of ibezapolstat locked into its target enzyme at a stunning resolution of 3.2 angstroms. This molecular snapshot confirmed that the drug binds to a pocket on the enzyme that is highly conserved across more than 220 different species of Gram-positive bacteria, explaining its potential for broad clinical utility.

“Our findings with regard to the structural biology of DNA pol IIIC in complex with inhibitors have important implications for the development of this novel class of antibiotics to treat high priority, multi-drug resistant, Gram-positive infections,” stated Dr. Wiep Klaas Smits, an Associate Professor at Leiden University Medical Center.

This isn’t just an academic victory. Visualizing how the drug works provides a blueprint for the future. As Acurx's Executive Chairman, Bob DeLuccia, noted, “These data will guide the rational design of new compounds with improved inhibitory activity and drug-like characteristics that will be crucial in addressing the pandemic of antimicrobial resistance.”

Escaping the Cycle of C. diff Recurrence

The most immediate promise of this precision approach is for patients trapped in the vicious cycle of C. diff infection (CDI). The CDC has labeled C. diff an “urgent threat,” responsible for nearly half a million infections and 30,000 deaths annually in the U.S. alone. For survivors, the battle is often far from over. Standard treatments, like the antibiotic vancomycin, can disrupt the gut so severely that they create the perfect conditions for a C. diff relapse. Recurrence rates hover between 20% and 40%, with each subsequent infection becoming harder to treat.

This is where ibezapolstat’s microbiome-sparing effect becomes critical. A healthy gut maintains a delicate balance of bile acids. Primary bile acids, secreted by the liver, can trigger the germination of dormant C. diff spores, while secondary bile acids, produced by healthy gut bacteria, inhibit them. By preserving these good bacteria, ibezapolstat allows the body to maintain its natural defense against recurrence. Clinical data has shown that patients treated with the drug have a more favorable ratio of protective secondary bile acids compared to those treated with vancomycin. The result is a potential one-two punch: curing the initial infection while simultaneously helping to prevent its return.

With ibezapolstat now ready for international Phase 3 trials for CDI, this represents a tangible hope for thousands who live in fear of the infection’s revolving door. The trial is designed not just to prove the drug is as good as the standard of care in curing the infection, but also to test if it is superior in preventing its devastating recurrence.

Forging a New Path Through a Broken System

The story of ibezapolstat is also a story about how to fix a broken system. Developing new antibiotics is scientifically challenging and, for many large pharmaceutical companies, not profitable enough to pursue. This has created a valley of death for promising new drugs. The Acurx-LUMC collaboration, co-funded by Health~Holland, a foundation tasked by the Dutch government to stimulate public-private partnerships (PPPs), offers a different model.

This PPP structure combines the agility and focus of a smaller biotech like Acurx, the deep scientific expertise and advanced infrastructure of a top academic institution like LUMC, and the public-interest funding of a government-backed entity. This de-risks the enormous cost of early-stage research and bridges the gap between a lab discovery and a viable clinical candidate. It’s a recognition that combating AMR is not just a commercial enterprise but a public good, requiring a collective, global effort.

The regulatory pathway for ibezapolstat reflects this urgency. It has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. FDA, as well as support from the European Medicines Agency (EMA). These programs are designed to incentivize and accelerate the development of drugs that address critical unmet needs.

The journey from a microscopic image to a pharmacy shelf is long and fraught with uncertainty. The upcoming Phase 3 trials will be the ultimate test of ibezapolstat’s promise against C. diff. Beyond that, Acurx is already exploring its potential against other urgent threats, including skin infections and even anthrax, a bioterrorism concern. For now, the detailed image from Leiden provides more than just data; it offers a clear vision of a smarter, more targeted way forward in a fight we cannot afford to lose.